Syndax Abandons IPF Trial, Pivoting Niktimvo Focus to Graft-Versus-Host Disease

NEW YORK, NY – October 12, 2026 — In the high-stakes arena of biopharmaceutical development, strategic agility is paramount. Syndax Pharmaceuticals (Nasdaq: SNDX) provided a stark reminder of this reality today, announcing the discontinuation of its idiopathic pulmonary fibrosis (IPF) program following the failure of its Phase 2 MAXPIRe trial. The study evaluating axatilimab—a colony-stimulating factor-1 receptor (CSF-1R) blocking antibody—did not meet its primary endpoint of halting the annualized rate of decline in forced vital capacity (FVC).

The drug was well-tolerated, showing a safety profile comparable to a placebo without any new safety signals. Yet, the lack of efficacy in preserving lung function forces the Waltham, Massachusetts-based company to abandon a major pipeline expansion opportunity. Instead, the firm is retreating to its stronghold, redirecting all resources toward its established and highly promising chronic graft-versus-host disease (cGVHD) franchise. For a company navigating the turbulent crosscurrents of modern drug development, this represents a textbook exercise in portfolio de-risking—cutting off non-viable branches to ensure the core enterprise thrives.

The Strategic Pivot: Doubling Down on a Core Franchise

Wall Street's reaction was swift and unforgiving. Shares of the commercial-stage biopharmaceutical company plummeted between 15% and 19.6% in after-hours trading. Prior to the announcement, the market had priced in the potential of a broad anti-CSF-1R disease expansion, with analysts maintaining "Strong Buy" ratings and average price targets hovering around $39. The sudden evaporation of the respiratory fibrosis indication represents a significant blow to the firm's non-oncology growth narrative.

The company's Price-to-Sales (P/S) ratio of 5.8 had already been trailing significantly below its historical median of 74.9, signaling deep market skepticism regarding future revenue growth outside of its established indications. Before the news broke, the firm's market capitalization stood at approximately $1.5 billion—a valuation heavily reliant on the successful expansion of axatilimab into broader fibrotic diseases.

"The MAXPIRe trial did not meet its primary endpoint, and we are disappointed by this outcome given the promising scientific rationale in IPF," stated Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax. "We sincerely thank the patients, caregivers, clinicians and study teams who participated. Axatilimab was well tolerated, with a safety profile consistent with prior studies supporting its continued development and use in cGVHD."

This retreat underscores a broader theme in global commerce: the necessity of ruthlessly pruning underperforming assets to protect core value. Much like the de-risking of global supply chains, shedding the dead weight of the IPF program allows leadership to insulate its valuation and focus on lasting competitive advantage. Chief Executive Officer Michael A. Metzger emphasized this recalibration, noting, "We remain highly focused on further advancing revumenib and axatilimab to frontline in the ongoing clinical trials which will unlock significant value for patients and shareholders."

The Graveyard of IPF Drugs: A Biological Labyrinth

Idiopathic pulmonary fibrosis is a chronic, progressive, and universally fatal lung-scarring disease that has long served as a graveyard for promising therapeutics. The current standard-of-care drugs—pirfenidone and nintedanib—merely slow disease progression and are plagued by tolerability issues that force many patients to discontinue use.

The failure of a CSF-1R inhibitor like axatilimab highlights the profound biological complexity of pulmonary fibrosis. The disease is characterized by multiple co-activated pathogenic pathways, including aberrant fibroblast proliferation and excessive extracellular matrix deposition. Targeting a single mechanism, even one as upstream as macrophage activation via CSF-1R, often proves insufficient against the robust, self-perpetuating fibrotic cascade that defines IPF.

Industry analysts have long noted a phenomenon in IPF drug development dubbed "regression to the truth," where therapies that show statistically significant biomarker improvements in small Phase 2 trials routinely fail to demonstrate meaningful FVC preservation in larger, longer-term Phase 3 studies. Recent years have seen late-stage failures from highly touted candidates like zinpentraxin alfa, ziritaxestat, and pamrevlumab.

Despite these daunting odds, the competitive landscape remains fiercely active. Over 70 companies are currently advancing more than 75 therapies. Competitors are exploring a wide array of novel mechanisms. Endeavor BioMedicine is advancing ENV-101, AstraZeneca is pushing its arginase inhibitor AZD8965, and Boehringer Ingelheim recently scored an approval for its PDE4 inhibitor nerandomilast. United Therapeutics is also awaiting a regulatory decision for nebulized Tyvaso in the IPF indication. In this crowded and unforgiving arena, Syndax's decision to exit rather than pour additional capital into a flawed asset reflects a disciplined, albeit painful, strategic calculus.

Recalibrating the Incyte Partnership

The MAXPIRe trial's failure reverberates beyond Syndax's internal pipeline, fundamentally altering the contours of its 2021 collaboration with Incyte. The exclusive worldwide co-development and co-commercialization license agreement was structured to capture value across multiple indications, with Incyte providing a $117 million upfront payment and a $35 million equity investment.

However, the deal also included up to $450 million in potential regulatory, development, and commercial milestone payments. With the IPF indication now permanently off the table, any milestones specifically tied to respiratory fibrosis will evaporate. Furthermore, the cost-sharing dynamics will shift. While Syndax funded the preliminary IPF development, Incyte held an option to co-fund late-stage trials—a financial commitment that is no longer necessary.

The commercialization agreement, which features a 50:50 profit share in the U.S. and double-digit royalties for Syndax on international sales, will now rely entirely on the commercial performance of the drug in cGVHD. While narrowing the partnership's focus, it also simplifies the commercial strategy, allowing both entities to align their marketing and clinical resources squarely on hematology.

The Path Forward in cGVHD

Fortunately for shareholders, axatilimab is not a one-trick pony. The drug is already FDA-approved under the brand name Niktimvo for the treatment of cGVHD in adult and pediatric patients weighing at least 40 kg who have failed at least two prior lines of systemic therapy. This approval was anchored by the pivotal AGAVE-201 study, which demonstrated a remarkable 75% overall response rate within the first six months of treatment, with a median time to response of just 1.5 months. Furthermore, 60% of these patients maintained their positive response at the 12-month mark, highlighting the drug's durability in a difficult-to-treat population.

Early commercial launch metrics have been highly encouraging. Incyte reported $36 million in second-quarter 2025 net sales for the drug, prompting an upward revision of its "Other Oncology" revenue guidance. Market analysts project that Niktimvo's peak sales could reach the $1 billion mark, provided the drug can successfully migrate into earlier lines of therapy.

This migration is the linchpin of Syndax's future growth. The company is actively advancing multiple frontline cGVHD trials that remain unaffected by the IPF setback. An ongoing Phase 2 trial is evaluating axatilimab in combination with ruxolitinib for newly diagnosed moderate to severe cGVHD. Interim safety data presented earlier this year indicated a manageable safety profile with no additive toxicity. Simultaneously, a Phase 3 trial is assessing the drug in combination with standard-of-care steroids for previously untreated patients.

Expected readouts from these critical trials are anticipated later in 2026 and early 2028. As the dust settles on the MAXPIRe disappointment, the narrative for Syndax transitions from pipeline breadth to commercial depth. The strategic imperative is now crystal clear: execute flawlessly on the frontline cGVHD expansion. In a macroeconomic environment that heavily penalizes clinical missteps, securing a blockbuster footprint in graft-versus-host disease is no longer just an expansion goal—it is an absolute necessity for long-term competitive advantage.